Industry News
Advent International Partially Exits Pharmaceutical Company Biotoscana (em português)
24 July 2017
Advent International has partially exited Uruguay-based pharmaceutical company Biotoscana through an initial public offering of Brazilian Depositary Shares (BDRs) on Brazil’s B3 stock exchange.
(Valor Econômico) A oferta pública inicial de certificados de ações (BDR) da fabricante de medicamentos de alta complexidade Biotoscana movimentou R$ 1,342 bilhão. O preço por BDR foi definido em R$ 26,50, no centro da faixa indicativa, que variava entre R$ 24,50 e R$ 28,50.
You may be interested in...
-
Allianz in LatAm; Across Capital’s ~USD115m Final Close; JICA, DFC, IDB Lab Newest Fund Commitments
-
Nominations Open for LAVCA Deal Awards; BTG Pactual TIG Secures USD500m for Reforestation Strategy
-
Nominations Open for 2025 LAVCA Women Investors in Private Capital; New LAVCA Q3 Industry Data; Vinci Partners Acquires Controlling Stake in Outback’s Brazilian Operations
-
Allianz X Leads USD300m Series E for Argentina’s Ualá
Allianz X led a USD300m Series E for Argentina-based fintech Ualá, with participation...